UBS analyst Brian Meredith raised the firm’s price target on Allstate to $160 from $150 and keeps a Buy rating on the shares as part of a broader research note on Insurance names. The analyst states that he favors commercial lines insurers going into Q4 earnings seasons as reinsurer valuations reflect favorable fundamentals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALL:
- Allstate price target raised to $153 from $147 at Piper Sandler
- Allstate announces zero net emissions commitment by 2030
- Allstate implements auto insurance rates for November
- Allstate replacing Accenture’s Droga5 for creative account, AdAge reports
- Allstate names Christine DeBiase chief legal officer